omitir hasta el contenido
The tumor immunoenvironment Ver este material de antemano
CerrarVer este material de antemano
Chequeando…

The tumor immunoenvironment

Autor: Michael R Shurin; Viktor Umansky; Anatoli Malyguine, (Principal Scientist)
Editorial: Dordrecht ; New York : Springer, ©2013.
Edición/Formato:   Libro-e : Documento : Inglés (eng)Ver todas las ediciones y todos los formatos
Base de datos:WorldCat
Resumen:
Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the  Leer más
Calificación:

(todavía no calificado) 0 con reseñas - Ser el primero.

Temas
Más materiales como éste

 

Encontrar un ejemplar en línea

Enlaces a este material

Encontrar un ejemplar en la biblioteca

&AllPage.SpinnerRetrieving; Encontrando bibliotecas que tienen este material…

Detalles

Género/Forma: Electronic books
Tipo de material: Documento, Recurso en Internet
Tipo de documento: Recurso en Internet, Archivo de computadora
Todos autores / colaboradores: Michael R Shurin; Viktor Umansky; Anatoli Malyguine, (Principal Scientist)
ISBN: 9789400762176 9400762178
Número OCLC: 833137657
Descripción: 1 online resource.
Contenido: Tumor Escape from Immune Recognition. MHC Class I Antigens and the Tumor Microenvironment / Natalia Aptsiauri ... [et al.] --
Tumor-Produced Immune Regulating Factors / Mads Hald Andersen, Jürgen C. Becker, Per thor Straten --
Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments / Yutaka Kawakami ... [et al.] --
T Cell Mulfunction in the Tumor Environment / Eitan Yefenof --
Signaling of Tumor-Induced Immunosuppression of Dendritic Cells / Yong Lu, Jing Yang, Qing Yi --
Tumor Microenvironment may Shape the Function and Phenotype of NK Cells Through the Induction of Split Anergy and Generation of Regulatory NK Cells / Anahid Jewett, Han-Ching Tseng --
Immune Regulators in the Tumor Immunoenvironment. The Role of Myeloid Derived Suppressor Cells in Cancer / Jonathan M. Weiss --
Macrophage Differentiation and Activation States in the Tumor Microenvironment / Jo A. Van Ginderachter --
Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets / Stephanie K. Watkins, Arthur A. Hurwitz --
The Role of Tumor Associated Neutrophils in Cancer / Zvi G. Fridlender --
Mast Cell Modulation of the Tumor Microenvironment / Sharon A. Oldford, Jean S. Marshall --
Regulatory T Cells in Patients with Cancer / Theresa L. Whiteside --
Tumor-Evoked Regulatory B Cells as Important Mediators of Cancer Escape / Catalina Lee-Chang, Monica Bodogai, Arya Biragyn --
Tumor Escape and Cancer Immunotherapy. Cancer Immunotherapy: Overview in Brief / Philipp Beckhove --
Programming of MDSC: New Opportunities for Targeted Therapy / Peter Svider ... [et al.] --
Therapeutic Targeting Regulatory T Cells in Tumor / Wei Wang, Weiping Zou --
ChemoImmunoModulation: Focus on Myeloid Regulatory Cells / Michael R. Shurin, Viktor Umansky --
Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing / Nishith Singh ... [et al.] --
Prophylactic Cancer Vaccines / Pamela L. Beatty, Olivera J. Finn --
Analyzing Immune Responses in Cancer. Approaches to Immunologic Monitoring of Clinical Trials / Lisa H. Butterfield, Lazar Vujanovic, Angela D. Pardee --
Evaluation of the Tumor Immunoenvironment in Clinical Trials / Anatoli Malyguine ... [et al.] --
Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer / Peiyuan Zhu ... [et al.] --
When Results of T cell Immune Monitoring Match/Do Not Match Clinical Outcomes of Tumor Vaccine Trials: What More Could and Should We Measure? / Paul V. Lehmann, Srividya Sundararaman. 1. Role of the immunological environment in cancer initiation, development and progression --
2. The metastatic microenvironment --
3. Tumor infiltration by immune cells: pathologic evaluation and a clinical significance --
4. Immunologic interpretation of cancer biology: impact on clinical outcome --
5. Development of antitumor cellular immunity --
6. The versatile world of inflammatory chemokines in cancer --
7. Inflammation, tumor progression, and immune suppression --
8. Pleiotropic and differential functions of IL-1 alpha and IL-1 beta shape the tumor microenvironment and affect the outcome of malignancies --
9. Impact of obesity and aging on the tumor immuno-environment --
10. MHC class I antigens and the tumor microenvironment --
11. Tumor-produced immune regulating factors --
12. Roles of signaling pathways in cancer cells and immune cells in generation of immunosupressive tumor-associated microenvironments --
13. T cell mulfunction in the tumor environment --
14. Signaling of tumor-induced immunosuppression of dendritic cells --
15. Tumor microenviroment may shape the funtion and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cells --
16. The roll of myeloid derived supporessor cells in cancer --
17. Macrophage differentiation and activation states in the tumor microenvironment --
18. Dendritic cells and cancer: development, dysfunction and therapeutic targets --
19. The role of tumor associated neutrphils in cancers --
20. Mast cell modulation of the microenvironment --
21. Regulatory T cells in patients with cancer --
22. Tumor-evoked regulatory B cells as important mediators of cancer escape --
23. Cancer immunotherapy: overview in brief --
24. Programming of MDSCMDSC: new opportunities for targeted therapy --
25. Therapeutic targeting regulatory T cells in tumor --
26. ChemoImmunoModulation: focus on myeloid regulatory cells --
27. Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing --
28. Prophylactic cancer vaccines --
29. Approaches to immunologic monitoring of clinical trials --
30. Evaluation of the tumor immunoenvironment in clinical trials --
31. Analysis of myeloid-derived suppressor cells in patients with cancer --
32. When results of T cell immune monitoring match/do not match clinical outcomes of tumor vaccine trials: what more could and should we measure?
Responsabilidad: Michael R. Shurin, Viktor Umansky, Anatoli Malyguine, editors.
Más información:

Resumen:

This book examines immune cell functioning in cancer, with a focus on both experimental animal results and human clinical trials.  Leer más

Reseñas

Reseñas contribuidas por usuarios
Recuperando reseñas de GoodReads…
Recuperando reseñas de DOGObooks…

Etiquetas

Ser el primero.
Confirmar este pedido

Ya ha pedido este material. Escoja OK si desea procesar el pedido de todos modos.

Datos enlazados


<http://www.worldcat.org/oclc/833137657>
library:oclcnum"833137657"
library:placeOfPublication
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/833137657>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
<http://viaf.org/viaf/304509435>
rdf:typeschema:Person
schema:familyName"Malyguine"
schema:givenName"Anatoli"
schema:name"Malyguine, Anatoli (Principal Scientist)"
schema:contributor
schema:copyrightYear"2013"
schema:datePublished"2013"
schema:description"Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions."@en
schema:description"1. Role of the immunological environment in cancer initiation, development and progression -- 2. The metastatic microenvironment -- 3. Tumor infiltration by immune cells: pathologic evaluation and a clinical significance -- 4. Immunologic interpretation of cancer biology: impact on clinical outcome -- 5. Development of antitumor cellular immunity -- 6. The versatile world of inflammatory chemokines in cancer -- 7. Inflammation, tumor progression, and immune suppression -- 8. Pleiotropic and differential functions of IL-1 alpha and IL-1 beta shape the tumor microenvironment and affect the outcome of malignancies -- 9. Impact of obesity and aging on the tumor immuno-environment -- 10. MHC class I antigens and the tumor microenvironment -- 11. Tumor-produced immune regulating factors -- 12. Roles of signaling pathways in cancer cells and immune cells in generation of immunosupressive tumor-associated microenvironments -- 13. T cell mulfunction in the tumor environment -- 14. Signaling of tumor-induced immunosuppression of dendritic cells -- 15. Tumor microenviroment may shape the funtion and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cells -- 16. The roll of myeloid derived supporessor cells in cancer -- 17. Macrophage differentiation and activation states in the tumor microenvironment -- 18. Dendritic cells and cancer: development, dysfunction and therapeutic targets -- 19. The role of tumor associated neutrphils in cancers -- 20. Mast cell modulation of the microenvironment -- 21. Regulatory T cells in patients with cancer -- 22. Tumor-evoked regulatory B cells as important mediators of cancer escape -- 23. Cancer immunotherapy: overview in brief -- 24. Programming of MDSCMDSC: new opportunities for targeted therapy -- 25. Therapeutic targeting regulatory T cells in tumor -- 26. ChemoImmunoModulation: focus on myeloid regulatory cells -- 27. Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing -- 28. Prophylactic cancer vaccines -- 29. Approaches to immunologic monitoring of clinical trials -- 30. Evaluation of the tumor immunoenvironment in clinical trials -- 31. Analysis of myeloid-derived suppressor cells in patients with cancer -- 32. When results of T cell immune monitoring match/do not match clinical outcomes of tumor vaccine trials: what more could and should we measure?"@en
schema:exampleOfWork<http://worldcat.org/entity/work/id/1216375612>
schema:genre"Electronic books."@en
schema:inLanguage"en"
schema:name"The tumor immunoenvironment"@en
schema:publisher
schema:url<http://dx.doi.org/10.1007/978-94-007-6217-6>
schema:url
schema:url<http://lib.myilibrary.com?id=508289>
schema:url<http://site.ebrary.com/id/10715927>
schema:url<http://public.eblib.com/EBLPublic/PublicView.do?ptiID=1106181>
schema:workExample

Content-negotiable representations

Cerrar ventana

Inicie una sesión con WorldCat 

¿No tienes una cuenta? Puede fácilmente crear una cuenta gratuita.